[ad_1]
Johnson & Johnson JNJ Shares,
gained 1.7% in pre-market trade on Thursday, the day after a study published in the New England Journal of Medicine showed that its COVID-19 vaccine candidate generated neutralizing antibody titers in around 800% of around 800 adult participants under 55 on day 57. (Some of the data from the Phase 1/2 clinical trial was released as a pre-print in September.) “In addition, during 71 days of follow-up after the first dose, antibody titers increased further and stabilized, suggesting the durability of the immune response elicited by Ad26.COV2.S, “the researchers wrote in the NEJM. The company’s investigational COVID-19 vaccine candidate is a single-dose vaccine, although the trial Phase 1/2 also includes a cohort of participants who receive two doses. It is also currently being tested in a Phase 3 clinical trial. J&J said he plans to share additional data from that trial on the immune response in adults over 55 later this month, and it also expects to release key data from the Phase 3 trial in January. Two vaccines have been cleared by the Food and Drug Administration to United States, both of which are vaccines mRNAs that require two doses. J&J is developing an adenovirus-based vaccine. J & J’s stock is up 7.7% from a year ago, while the S&P 500 SPX,
gained 15.8%.
Source link
